Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer
Open Access
- 1 August 2007
- journal article
- research article
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 55 (8) , 867-875
Abstract
Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success. Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy. In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples ( n = 92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125. Among all ovarian cancer types, 72%, 61%, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. Expression level of these antigens was significantly ( p70%), a heterogeneous labeling pattern was observed (only 30–40% of the cancer cells within the sample were labeled). However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled. Our data indicate that the heterogeneous expression of cancer antigens appears to be a major obstacle in antibody-guided therapy, and this can be overcome by multiple antigen targeting. Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125. (J Histochem Cytochem 55: 867–875, 2007)Keywords
This publication has 31 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)Laboratory Investigation, 2006
- New tumor markers: CA125 and beyondInternational Journal of Gynecological Cancer, 2005
- Potential markers that complement expression of CA125 in epithelial ovarian cancerGynecologic Oncology, 2005
- Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal DiseaseClinical Cancer Research, 2004
- Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivoInternational Journal of Pharmaceutics, 2004
- Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclideInternational Journal of Gynecological Cancer, 2003
- Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic DiseaseThe Oncologist, 2002
- Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I StudyCancer Biotherapy and Radiopharmaceuticals, 2001
- Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancerEuropean Journal of Cancer, 1995